Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting
- 28 February 2005
- journal article
- research article
- Published by Elsevier BV in Urology
- Vol. 65 (2), 300-305
- https://doi.org/10.1016/j.urology.2004.09.030
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Benign prostatic hyperplasia: a progressive disease of aging menUrology, 2003
- Storage (Irritative) and Voiding (Obstructive) Symptoms as Predictors of Benign Prostatic Hyperplasia Progression and Related OutcomesEuropean Urology, 2002
- Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overviewUrology, 2001
- EAU Guidelines on Benign Prostatic Hyperplasia (BPH)European Urology, 2001
- Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasterideUrology, 2000
- Prostate Volume and Serum Prostate–Specific Antigen as Predictors of Acute Urinary RetentionEuropean Urology, 2000
- Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placeboUrology, 1999
- Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasiaUrology, 1999
- Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waitingUrology, 1999
- 5-YEAR OUTCOME OF SURGICAL RESECTION AND WATCHFUL WAITING FOR MEN WITH MODERATELY SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA: A DEPARTMENT OF VETERANS AFFAIRS COOPERATIVE STUDYJournal of Urology, 1998